RheumNow Live kicks off its second annual meeting - a little, big meeting in Fort Worth - in just 2 weeks and I think you should be there.

Today, the American College of Rheumatology (ACR) published the 2020 Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases.

NICE has commissioned an update to the 2010 British Society for Rheumatology guideline for the management of giant cell arteritis, and proposed a total of 19 recommendations for the diagnosis and treatment of GCA.

Dr. Jack Cush reviews the highlights from the 2020 RWCS meeting in Maui, Hawaii.

The PEXIVAS study showed that plasma exchange did not reduce the incidence of death or ESKD in patients with severe ANCA–associated vasculitis.

Shingles infection has been historically linked to an increased risk of stroke. A new study found that Zoster Vaccine Live, one type of shingles vaccination, may prevent stroke in some older adults.

Dr Jack Cush reviews the news and journal articles from the past week on RheumNow.com

The European League Against Rheumatism (EULAR) has established an international collaborative group (EULAR SS Task Force) to develop the first EULAR evidence and consensus-based recommendations for the management of patients with Sjogens syndrome (SjS).

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

QD Clinic - Lessons from the clinic. In this video: Patients stable on a biologic need guidance on when, and if, they can stop their biologic.

A controlled clinical trial has shown that giving the IL-6 receptor antibody, tocilizumab (TCZ), to  patients with Takayasu arteritis (TAK) results in clinical efficacy and has a steroid sparing efffect.

Dr. Jack Cush reviews the journal reports and news from RheumNow.com.
Be sure to register for RheumNow Live 3/13/2020 in Fort Worth
Rheumnow.live.

NEJM has published the results of the TULIP2 trial with anifrolumab, an alpha interferon blocker, in the treatment of systemic lupus erythematosus, showing significant improvement (over placebo) in multiple lupus outcome measures, including BICLA, SRI-4, CLASI and others.

Lancet Rheumatology has reported the results of a multicenter follow-up study of systemic lupus erythematosus (SLE) patients showing that organ damange is linked to glucocorticoid use, independent of clinical or serological disease activity.

Statin-induced myositis, often with anti-HMGCR autoantibodies can be difficult to manage, Arthritis Research & Therapy yhas published the experience of 55 patient with HMGCR myopathy, demonstrating that while steroid management may be reasonable in select patients, the use of tr

A EULAR task force has reviewed the medical literature and developed evidence-based recommendations for the management of antiphospholipid syndrome (APS) in adults. They note that a high-risk antiphospholipid antibody (aPL) profile is associated with greater risk for thrombotic and obstetric APS.

The European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) have jointly developed new classification criteria for systemic lupus erythematosus (SLE); prompted by the need for criteria that were both highly sensitive and specific. The net result is improved sensitivity and specificity, but the use of positive ANA requirement along with a longer list of weighted criteria ensures its utility in SLE research (including early or latent SLE), but not clinical practice.

Dr. Jack Cush reviews the news from the past week on RheumNow.com, just in time for Christmas!

Belimumab has been studied in an active lupus nephritis, phase 3 trial call BLISS-LN and shown to be effective as measured by  trial of belimumab for the treatment of active lupus nephritis in adult patients.